Ozempic (Semaglutide)

Semaglutide, the active ingredient in Ozempic, the active ingredient in Ozempic, is a GLP‑1 receptor agonist presented as a 0.25 mg/0.5 ml pre‑filled pen for subcutaneous injection use. It is indicated for improving glycaemic control in adults with type 2 diabetes mellitus and may aid weight management in this population.

GNH USA supplies Ozempic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ozempic is a GLP‑1 receptor agonist that targets the incretin pathway to improve blood glucose regulation.

- Type 2 diabetes mellitus: Improves glycaemic control and reduces HbA1c levels. - Cardiovascular risk reduction: Lowers the risk of major adverse cardiovascular events in adults with established cardiovascular disease. - Weight management adjunct: Supports modest weight loss when used alongside diet and exercise in adults with type 2 diabetes.

Adverse reactions reported with semaglutide vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often related to nausea. - Diarrhoea: loose stools, typically transient. - Constipation: reduced bowel movements. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute kidney injury: sudden decline in renal function. - Medullary thyroid carcinoma risk: potential association with thyroid tumours. - Allergic reactions: including anaphylaxis and severe skin eruptions.

When prescribing Ozempic, clinicians should consider several safety aspects.

- Assess renal function: monitor kidney health before and during therapy. - Monitor cardiovascular status: watch for signs of heart failure . - Evaluate thyroid health: screen for personal or family history of medullary thyroid carcinoma. - Review medication history: check  for  potential  drug  interactions  that  may  affect  the  pharmacokinetics  of  Oz  "). - Adjust  ").   "). \